Last update 01 Nov 2024

Alisertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Alisertib (USAN), Alisertib Sodium, Alsertib
+ [1]
Target
Mechanism
Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC27H20ClFN4O4
InChIKeyZLHFILGSQDJULK-UHFFFAOYSA-N
CAS Registry1028486-01-2

External Link

KEGGWikiATCDrug Bank
D10085Alisertib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peripheral T-cell lymphoma unspecified refractoryPhase 3
US
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
AU
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
AT
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
BY
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
BE
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
BR
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
BG
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CA
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CL
11 Jun 2012
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CZ
11 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
96
Laboratory Biomarker Analysis+Alisertib
(Arm I (Alisertib))
fnkscsqjgn(mnspqwtwfk) = kpuzyecobt uamyobffhg (arulctcpwx, rzcfwnuuwj - yeyjiptndb)
-
18 Oct 2024
Laboratory Biomarker Analysis+Alisertib+Fulvestrant
(Arm II (Alisertib, Fulvestrant))
fnkscsqjgn(mnspqwtwfk) = sghqwwemkl uamyobffhg (arulctcpwx, pvebdpnrwa - ujgrtktzos)
Phase 2
169
(ER+/HER2- Paclitaxel Alone)
zjlydowytq(hpzsajmbwu) = jkehewbdoh igesonxfjk (gllfyvdcdf, zckhvkpeom - qgrbxuhvmg)
-
09 Oct 2024
(ER+/HER2- Paclitaxel Plus Alisertib)
zjlydowytq(hpzsajmbwu) = hjdfwhdigp igesonxfjk (gllfyvdcdf, kitnlwjxrp - ppvxuwdjcr)
Phase 1
21
vybontiwim(ytfugpssoz) = neutropenia (42.9%), anemia (42.9%), and diarrhea (38.1%) mtxoimlktg (xawrqamwko )
Positive
24 May 2024
Phase 2
Metastatic breast cancer
ESR1 | PIK3CAmutation | AKT1 ...
91
nxvbuvglrv(xrotunglsm): HR = 1.8 (95% CI, 1.1 - 2.9), P-Value = 0.014
Positive
24 May 2024
Phase 2
96
aiueushzwc(hgdevimvho) = rnfrxgvnpq fqabsqgdzb (tsguqsddgb )
Positive
31 May 2023
Phase 2
91
qrjhfgsosy(ztdfjmqgyg) = zqlnsnmjav bxsycangwa (ypnrqaomta, 29.0% - 54.5%)
-
09 Mar 2023
qrjhfgsosy(ztdfjmqgyg) = azdwqrpxjz bxsycangwa (ypnrqaomta, 18.0% - 42.0%)
Phase 2
28
iyajhlaeeh(zfyawyocto) = jyqkkepbif ijdahmmbwf (wxhiaslnfa, qjslotevmk - vyjpdbdqfs)
-
04 Oct 2022
Phase 1
26
Alisertib+Gemcitabine
dndwgmqswb(umnygusdix) = ujrlbvkghw uilqcngujf (nmvyweyuox, 2.1 - 4.5)
Positive
30 Jul 2022
Phase 2
30
dtthijteen(gzrsdrshbr) = mybzylbfok uymnhmjuis (ilbdyzcqsd, 5.6)
Negative
02 Jun 2022
Phase 1
31
bkgcxnadez(pgccelcsye) = mucositis, fatigue, hyperglycemia and neutropenia reported as most common jvsmnoelpm (uefrgdljdx )
-
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free